Ground News

News from Cardiol Therapeutics

Your destination for news from Cardiol Therapeutics. See how Cardiol Therapeutics’s media bias impacts the breaking news stories of today.

In total, 4 have been published by Cardiol Therapeutics which Ground News has aggregated in the past 3 months.

The Ground News media bias check for Cardiol Therapeutics is . Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

We’ve assigned a rating of Unknown factuality to Cardiol Therapeutics. You can read more about how we’ve determined Cardiol Therapeutics’s credibility and reliability as a news source here: https://ground.news/rating-system.

Information about Cardiol Therapeutics

Where is Cardiol Therapeutics located?Cardiol Therapeutics's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Cardiol Therapeutics News

Maryland · Maryland

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application. Data from Cardiol’s Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific…See the Story

You've scrolled to the bottom of the feed, there are no more stories.

News from Cardiol Therapeutics

News from Cardiol Therapeutics

Information about Cardiol Therapeutics

Media Bias Ratings

Factuality

Ownership

Top Cardiol Therapeutics News

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

News from Cardiol Therapeutics

Information about Cardiol Therapeutics

Media Bias Ratings

Factuality

Ownership

Top Cardiol Therapeutics News

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Announces Publication of Research in theJournal of the American College of Cardiology: Basic to Translational Science that Supports Development of its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure